CTOs on the Move

Hilco/Wilson Smart Optical Solutions

www.hilco-usa.com

 
Hilco/Wilson Smart Optical Solutions is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plainville, MA. To find more information about Hilco/Wilson Smart Optical Solutions, please visit www.hilco-usa.com
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Currance

Formed by revenue cycle industry leaders, Currance is a Rev-Cycle Performance solutions company focused on empowering community providers, physician practices and healthcare systems to achieve and sustain yield performance improvement. Currance`s strategy of Performance Partnering supports your own team by offering everything needed to drive yield performance: an intelligent technology platform that integrates with existing systems, tailored solutions, and professional services for operationalizing the technology and sustaining exceptional results. The Currance approach encompasses best-in-class knowledge of revenue cycle management, proprietary technologies, and the proven ability to engage, train, and mentor employees, adding value to clients` organizations. We embrace a mindset rooted in science and operational experience, enabling highly efficient processes and precise workflow design that improve profitability and help build patient-centered, high-performing organizations.

Riverside Physician Service

Riverside Physician Service is a Bradenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metropolitan Health Networks

Metropolitan Health Networks, Inc. is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DocuMed

DocuMed Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.